Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 13/20 | 0.81 |
| ▸ | ESR1 | P03372 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.74 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.74 |
| ▸ | SHBG | P04278 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | AR | P10275 | 1/20 | 0.74 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.74 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5324130 | 0.90 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL3867797 | 0.90 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL13266169 | 0.90 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL19393201 | 0.90 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL17775797 | 0.88 | STS (0.79) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL8937142 | 0.88 | STS (0.78) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL14154435 | 0.88 | STS (0.78) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL27047081 | 0.87 | STS (0.77) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL4903623 | 0.86 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL4903619 | 0.86 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0874642-B1 | SUSTAINED RELEASE DRUG FORMULATIONS | SOD CONSEILS RECH APPLIC (FR) | 2003-05-02 | — | — | EP | claimed |
| US-4622181-A | Process for producing an estrone acetal | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1986-11-11 | — | — | US | claimed |
| US-3963766-A | Process for separation of 19-nor-Δ4 -androstene-3,17-dione | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1976-06-15 | — | — | US | claimed |
| JP-60169496-A | — | — | None | — | — | JP | disclosed |
| CN-112492881-A | Reagent for mass spectrometry | 豪夫迈·罗氏有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-7198776-B2 | Metal complex compounds | GE HEALTHCARE AS (NO) | 2007-04-03 | — | — | US | disclosed |
| US-20050090653-A1 | Metal complex compounds | GE HEALTHCARE AS (NO) | 2005-04-28 | — | — | US | disclosed |
| EP-1465669-A1 | METAL COMPLEX COMPOUNDS | Amersham Health AS (NO) | 2004-10-13 | — | — | EP | disclosed |
| US-20030170173-A1 | Contrast agents | GE HEALTHCARE AS (NO) | 2003-09-11 | — | — | US | disclosed |
| WO-2003045442-A1 | METAL COMPLEX COMPOUNDS | AMERSHAM HEALTH AS (NO) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003045441-A1 | CONTRAST AGENTS FOR THE IN VIVO DETECTION OF ENZYME ACTIVITY | AMERSHAM HEALTH AS (NO) | 2003-06-05 | — | — | WO | disclosed |
| WO-1997026015-A1 | SUSTAINED RELEASE DRUG FORMULATIONS | DELAB (FR) | 1997-07-24 | — | — | WO | disclosed |
| US-4622181-A | Process for producing an estrone acetal | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1986-11-11 | — | — | US | disclosed |
| US-4622181-A | Process for producing an estrone acetal | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1986-11-11 | — | — | US | disclosed |
| US-4622181-A | Process for producing an estrone acetal | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1986-11-11 | — | — | US | disclosed |
| JP-S60169496-A | PREPARATION OF ESTRONE ACETAL | MITSUBISHI CHEM IND LTD | 1985-09-02 | — | — | JP | disclosed |
| WO-1984003094-A1 | PROCESS FOR PREPARING ESTRONE ACETAL | MITSUBISHI CHEM IND (JP) | 1984-08-16 | — | — | WO | disclosed |
| WO-1984003094-A1 | PROCESS FOR PREPARING ESTRONE ACETAL | MITSUBISHI CHEM IND (JP) | 1984-08-16 | — | — | WO | disclosed |
| US-3963766-A | Process for separation of 19-nor-Δ4 -androstene-3,17-dione | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1976-06-15 | — | — | US | disclosed |
| US-3963766-A | Process for separation of 19-nor-Δ4 -androstene-3,17-dione | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170173-A1 | Contrast agents | GBA1, RNASE1, MAN2B1 | STS 854/4885ESR1 4572/4885CYP3A4 1403/4885 |
| US-20050090653-A1 | Metal complex compounds | ME3, MPI, ME2 | STS 2042/4885ESR1 3980/4885CYP3A4 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.